BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25351457)

  • 1. Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain.
    Mercadante S; Vellucci R; Cuomo A; Adile C; Cortegiani A; Valle A; Villari P; Casuccio A
    Support Care Cancer; 2015 May; 23(5):1349-54. PubMed ID: 25351457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of intranasal fentanyl spray in cancer patients with breakthrough pain.
    Thronæs M; Popper L; Eeg M; Jaatun E; Kvitberg M; Kaasa S
    Clin Ther; 2015 Mar; 37(3):585-96. PubMed ID: 25641199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period.
    Kress HG; Orońska A; Kaczmarek Z; Kaasa S; Colberg T; Nolte T
    Clin Ther; 2009 Jun; 31(6):1177-91. PubMed ID: 19695386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen.
    Mercadante S; Prestia G; Adile C; Casuccio A
    J Pain; 2014 Jun; 15(6):602-7. PubMed ID: 24561001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial.
    Mercadante S; Radbruch L; Davies A; Poulain P; Sitte T; Perkins P; Colberg T; Camba MA
    Curr Med Res Opin; 2009 Nov; 25(11):2805-15. PubMed ID: 19792837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain.
    Kaessner N; Nave R; Roepcke S; Facius A; Lahu G
    Int J Clin Pharmacol Ther; 2012 Sep; 50(9):665-77. PubMed ID: 22784611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain.
    Kaasa S; Moksnes K; Nolte T; Lefebvre-Kuntz D; Popper L; Kress HG
    J Opioid Manag; 2010; 6(1):17-26. PubMed ID: 20297611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
    Mercadante S; Ferrera P; Adile C; Casuccio A
    J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
    Plock N; Facius A; Hartmann L; Baumann S; Nave R
    Int J Clin Pharmacol Ther; 2013 Jun; 51(6):495-508. PubMed ID: 23611571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
    Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
    Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Oral or Nasal Fentanyl for Treatment of Breakthrough Pain in Cancer Patients: A Systematic Review.
    Rogríguez D; Urrutia G; Escobar Y; Moya J; Murillo M
    J Pain Palliat Care Pharmacother; 2015 Sep; 29(3):228-46. PubMed ID: 26458018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen.
    Mercadante S; Prestia G; Casuccio A
    Curr Med Res Opin; 2013 Nov; 29(11):1527-32. PubMed ID: 23869428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
    Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
    Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fentanyl buccal tablet.
    Messina J; Darwish M; Fine PG
    Drugs Today (Barc); 2008 Jan; 44(1):41-54. PubMed ID: 18301803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan.
    Chiou TJ; Chao TC; Chao TY; Huang JS; Chang YF; Wang CH
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1179. PubMed ID: 32721110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study.
    Yen TY; Chiou JF; Chiang WY; Su WH; Huang MY; Hu MH; Wu SC; Lai YL
    Medicine (Baltimore); 2018 Jul; 97(30):e11593. PubMed ID: 30045291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sublingual fentanyl orally disintegrating tablet at doses determined from oral morphine rescue doses in the treatment of breakthrough cancer pain.
    Shimoyama N; Gomyo I; Teramoto O; Kojima K; Higuchi H; Yukitoshi N; Ohta E; Shimoyama M
    Jpn J Clin Oncol; 2015 Feb; 45(2):189-96. PubMed ID: 25378647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of low doses of a sublingual fentanyl formulation for breakthrough pain in patients receiving low doses of opioids.
    Mercadante S; Adile C; Cuomo A; Aielli F; Marinangeli F; Casuccio A
    Support Care Cancer; 2017 Feb; 25(2):645-649. PubMed ID: 27744534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial titration with 200 μg fentanyl buccal tablets: a retrospective safety analysis in Korean cancer patients.
    Kwon MY; Cho HN; Koo DH; Lee YG; Oh S; Lee SS
    Korean J Intern Med; 2018 May; 33(3):577-584. PubMed ID: 28111431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.